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Introduction
Higher level of blood lipid including circulat-
ing low-density lipoprotein-cholesterol (LDL-C)
significantly enhances the potential risk for the
coronary artery disease (CAD) and myocardial
infarction (MI)(1). Increasing concentrations of
serum lipids accelerates atherosclerosis and the
development of CAD(2). Current experimental data
from genetic and epidemiologic studies suggest
that inheritance and environmental factors affect
the plasma level of lipids. Therefore, to prevent
and treat cardiovascular diseases therapeutic
researches have been focused on the designation of
medicines that lower LDL-C levels(3, 4).
Numerous clinical trials have used HMG-
CoA reductase inhibitors (statins) as a therapeutic
measurement to reduce LDL-C levels and cardio-
vascular complications, and yet several other drugs
are under scientific investigation. In this regard, it
is necessary to scrutinize signaling pathways that
regulate LDL-C metabolism to discover novel fun-
damental targets(5). One of these potential targets
that influences plasma LDL-C concentration and
susceptibility to CAD is pro-protein convertase
subtilisin/kexin type 9 (PCSK9)(6, 7). 
PCSK9 is a circulating protein and by
decreasing the half-life of LDL-receptor (LDL-R)
controls the plasma levels of LDL-C(8). Mutations
in the PCSK9 gene are either associated with the
Acta Medica Mediterranea, 2015, 31: 1435
Received May 30, 2015; Accepted November 02, 2015
ABSTRACT
Pro-protein convertase subtilisin/kexin type 9 (PCSK9) has been implicated in the regulation of the plasma levels of LDL-cho-
lesterol. The SNP rs11591147 variant in PCSK9 gene is associated with low levels of LDL and reduced risk of coronary artery disea-
se (CAD) in various populations. We therefore, investigated the association and protective role of the SNP rs11591147 with CAD in
94 patients and 94 healthy participants as controls. rs11591147 T>G was genotyped in all subjects by TaqMan Probe Real Time
PCR, although we could not observe neither positive or insignificant association between SNP genotypes with CAD incidence. Allele
frequencies also remained insignificant after performing comparison analyses between cases and controls. LDL-cholesterol and total
cholesterol levels were not associated with the genotypes. Our data indicated that CAD or the plasma level of LDL-cholesterol was
not associated with the reduction of CAD incidence in Iranian population, even in a population with high frequency of lipid-connec-
ted CAD risk factors. Prospective investigations should include more cases to accurately analyze the effect of SNP rs11591147 in
protecting patients from CAD.
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gene overexpression or deficiency. Upregulation of
the gene in mice significantly reduced the amount
of LDL-R in liver; however, mice models deficient
in PCSK9 demonstrated a correspondingly
increased level of LDL-R with active uptake of cir-
culating plasma LDL-C (9-12). Overall, there is a
direct relationship between levels of PCSK9 and
LDL-C, where PCSK9 overexpression promotes
high LDL concentrations and vice versa. PCSK9 is
a glycoprotein with 692 amino acids and causative
mutations in the gene are known to be highly asso-
ciated with familial hypercholesterolemia(5,13).
PCSK9 level and thus, LDL-C concentrations vary
considerably among individuals and different pop-
ulations, but it has been suggested that DNA
sequence variations of the gene are responsible for
this variability and risk of CAD(2,8). 
Progressive advances in large-scale genomics’
studies have yielded useful approaches such as
genome-wide association study (GWAS) to scan
for common single nucleotide polymorphisms
(SNPs) and their association with a particular phe-
notype. This technology is capable of whole-
genome genotyping to find about 500,000 previ-
ously identified SNPs or test for novel genetic loci
associated with medical complications(1). The asso-
ciation of rs11591147 T>G in PCSK9 gene with
LDL-C levels and risk of CAD has been shown in
several GWAS and replication reports(1,2,5,8,14,16).
Sequence variants with consistent relation to the
alterations in blood lipid levels could be used as a
valuable prognostic tool to predict the risk for
CAD in a subsequent population. Moreover, there
is a strong connection between statistically associ-
ated SNPs at PCSK9 gene in several populations.
Thus, studies of groups from different ethnic ori-
gins are required to devise more comprehensive
conclusions about interindividual variations and
the related effect on CAD. Therefore, this study
assessed the association between PCSK9 SNP
rs11591147 variants with risk of CAD in Iranian
population.
Materials and methods
Study population
The ethics review board of the Shahid
Beheshti University of Medical Sciences approved
the study; the participants gave written informed
consent. 94patients were cases with ages over 40
who underwent coronary angiography and revealed
stenosis of ≥ 50% in at least one coronary artery.
94 control group participants were healthy individ-
uals with no previous history of CAD and MI. All
subjects submitted a standardized questionnaire
regarding conventional cardiovascular risk factors.
The collected data included age, sex, cigarette
smoking, hypertension (systolic and diastolic blood
pressures-SBP and DBP), hypercholesterolemia
(HDL-C and LDL-C levels), diabetes (fasting
blood sugar-FBS), body mass index (BMI), triglyc-
eride level, height, and weight. Using the High
Pure PCR Template Preparation Kit (Roche,
Germany), whole genomic DNA was extracted
from all blood samples.
Genetic analysis
Spectrophotometry (Nanodrop 1000, Thermo
Fisher Scientific, USA) and gel electrophoresis
were used to quantify and qualify the extracted
DNA. rs11591147 T>G variants were genotyped
by TaqMan Probe Real Time PCR (LightCycler 96,
Roche, Germany).
Statistical analysis
All procedures were performed by SPSS 21
software (Chicago, USA). The association of the
risk factors with CAD was evaluated by testing for
the difference between patients and control group
by means of a chi-square test for categorical data.
Student’s t -test was used for continuous data, pro-
viding P-values, odds ratios (ORs), and 95% confi-
dence intervals (CIs) to estimate the strength of the
association. Comparisons were performed by one-
way ANOVA and Kruskal–Wallis test.
Additionally, the post hoc test and Mann–Whitney
U test were used for comparison across the groups.
Multivariate regression test was used to compare
the effect of independent variables such as BMI,
LDL-C level, gender, and age on SNP genotypes
and CAD. Gene counting determined genotype and
allele frequencies. Chi-square test was also per-
formed to test whether the genotype and allele fre-
quencies are in accord to the Hardy-Weinberg
equilibrium. Values of P<0.05 were admitted to
indicate statistical significance.
The clinical and biochemical characteristics
of the study population are summarized in Table 1.
Plasma levels of LDL-C, FBS, and triglyceride
were significantly higher among subjects with
CAD, but controls revealed an increased level of
HDL. The incidence of BMI, hypertension, and
mean age remained significantly higher in CAD
cases. There was no significant difference between
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sex and total cholesterol levels in the groups. No
deviation from Hardy-Weinberg equilibrium was
detected among the PCSK9 rs11591147 variants in
both groups. Table 2 shows the genotype and allele
frequencies of the PCSK9 rs11591147 G>T SNP in
patients and controls. Among CAD cases all of the
patients were homozygous for G allele and none of
the cases showed GT or TT genotypes. For the 94
healthy participants included, 91(97%) were with
GG genotype while GT heterozygotes constituted
3% of the healthy group (Table 2). Similar to CAD
group, we could not observe any healthy partici-
pant with the TT genotype. 
Results
Although PCSK9 mutations and underexpres-
sion have been discovered in association with
reduced level of LDL-C in serum, only few inves-
tigations have described and replicated the associa-
tion of rs11591147 (R46L) genetic variants with
potential risk of CAD(2, 15, 17-19). Benn et al. per-
formed a GWA study and used meta-analysis of
previous reports to describe the significant protec-
tive role of SNP rs11591147 in ischemic heart dis-
ease, MI, and mortality in more than 10,000 partic-
ipants from white and of Danish descent(20). The
primary purpose of this study was to replicate the
association between SNP rs11591147 variants and
the risk of CAD in Iranian population. However,
this study could not detect a significant association
between any variants of the SNP rs11591147 with
CAD risk.
Guella et al. 2010 observed the positive asso-
ciation between rs11591147 carriers and lower
LDL-C levels, as well as reduced risk for MI
among Italians (OR = 0.67; 95% CI = 0.46-0.97;  P
= 0.036)(2), which is inconsistent with our findings.
Another GWAS approach aimed to reveal the asso-
ciation between PCSK9 circulating level with its
interindividual variants and plasma LDL in 5,722
subjects in Stockholm. The study confirmed the
positive correlation between rs11591147 with
decreased plasma levels of PCSK9 (P = 2.20×10-
15) and LDL-C (P = 2.05×10-14). There was no
relation between the SNP variants with insulin and
triglyceride levels(8). In 1828 whites from the
Coronary Artery Risk Development In Young
Adults study, Huang and colleagues described the
association of rs11591147 variant with LDL-C lev-
els, which was significantly decreased at age 18 in
SNP carriers (84.4 mg/dL, p < 0.001)(14).
In Cohen’s study whites showed similar
results to those of Huang report, and rs11591147
carriers revealed about 50% lower CAD occur-
rence in follow-up period (P = 0.003)(15). 
PCSK9 impacts cholesterol levels by inducing
LDL receptor degradation, but the mechanism of
action of this process is largely unidentified.
Studies showed that PCSK9 suppresses LDL
receptor to inhibit LDL uptake, but mice depleted
for PCSK9 present enhanced LDL clearance(11, 12).
Thus, further work should aim to investigating the
relation between PCSK9 variants and assessing the
effects by functional assays on LDL metabolism to
improve therapeutic applications of CAD compli-
cations.
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